You are here

RNAi

With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam

With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam

Fierce Pharma

primary hyperoxaluria type 1

Flag link:

Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension

Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension

BioSpace

Flag link:

AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress

AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress

BioSpace

Alzheimer's disease

clinical trials

Flag link:

4DMT provides clinical programme updates for its wet AMD gene therapy

4DMT provides clinical programme updates for its wet AMD gene therapy

Clinical Trials Arena

4D Molecular Therapeutics

wet age-related macular degeneration

Flag link:

Janssen Returns Phase I NASH Candidate to Arrowhead

Janssen Returns Phase I NASH Candidate to Arrowhead

BioSpace

Arrowhead Pharmaceuticals

Flag link:

Alnylam scraps trial in rare eye disorder, blaming drug price reforms

Alnylam scraps trial in rare eye disorder, blaming drug price reforms

Pharmaphorum

Stargardt disease

Inflation Reduction Act

Flag link:

Biotech’s near-term key catalysts

Biotech’s near-term key catalysts

EP Vantage

Alzheimer's disease

Arrowhead Pharmaceuticals

Flag link:

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

Businesswire

Alnylam Pharmaceuticals

clinical trials

immunoglobultin A nephropathy

Flag link:

Alnylam's potential fourth RNAi approval delayed three months, but impact likely to be 'modest'

Alnylam's potential fourth RNAi approval delayed three months, but impact likely to be 'modest'

Endpoints

Flag link:

Another biotech shuffles its C-suite as Silence CEO steps down

Another biotech shuffles its C-suite as Silence CEO steps down

Endpoints

Silence Therapeutics

Flag link:

GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead

GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead

Fierce Biotech

Arrowhead Pharmaceuticals

Flag link:

Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna

Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna

Fierce Biotech

Dicerna Pharmaceuticals

Flag link:

Dicerna's RNAi drug shows 'inconsistent' results in rare kidney disease, tanking shares despite trial win

Dicerna's RNAi drug shows 'inconsistent' results in rare kidney disease, tanking shares despite trial win

Endpoints

Primary Hyperoxaluria

clinical trials

Flag link:

Alnylam's Study on Renal Treatment Shows Promising Results In Phase III Trial

Alnylam's Study on Renal Treatment Shows Promising Results In Phase III Trial

BioSpace

clinical trials

Flag link:

Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis

Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis

Endpoints

Arrowhead Pharmaceuticals

animal research

cystic fibrosis

Flag link:

Eli Lilly Collab Scores IND Approval for Dicerna's RNAi Cardiometabolic Drug

Eli Lilly Collab Scores IND Approval for Dicerna's RNAi Cardiometabolic Drug

BioSpace

clinical trials

cardiometabolic diseases

Flag link:

Novartis’s big wager on RNAi approaches the finish line

Novartis’s big wager on RNAi approaches the finish line

EP Vantage

Flag link:

Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?

Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?

Motley Fool

Vir Biotechnology

Flag link:

Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug

Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug

Endpoints

Arrowhead Pharmaceuticals

Flag link:

Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants

Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants

Fierce Biotech

clinical trials

Flag link:

Pages